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Every noble work is at ﬁ  rst impossible.
Th  omas  Carlyle
Th  e quest for a therapeutic to ameliorate ischemic and 
traumatic brain injury is certainly a noble ideal, but, thus 
far, a futile endeavor. In the previous issue of Critical 
Care, Loetscher and colleagues [1] provided further 
evidence that the inert, noble gases may have ameliorative 
properties in the setting of acute neuronal injury. Stimu-
lated by a shared interest in the neuroprotective proper-
ties of another noble gas, xenon [2-4], they have shifted 
their focus to argon, a gas that is more abundant and 
cheaper to obtain. In their current investigation, they 
demonstrate that argon is neuroprotective when applied 
after an oxygen-glucose deprivation (OGD) or traumatic 
injury in organotypic hippocampal slice cultures in vitro. 
Th   e models the authors employ are robust; the cultured 
slices have intact synaptic networks, replicating the in 
vivo setting well; OGD is a well-described simulation of 
ischemic brain injury [3]; similarly, the trauma model repli-
cates the clinical situation [2]. Loetscher and colleagues 
report a dose-responsive neuroprotective eﬀ  ect, with 50% 
argon appearing to be the optimal concentration for 
neuroprotection. Furthermore, argon was even neuro-
protective when administered 3  hours after the injury. 
Although this report used only in vitro models, it is a 
foundation on which to base further studies that may 
further reveal argon’s potential in a ﬁ  eld largely bereft of 
interventions to improve neurological outcome from 
ischemic or traumatic brain injury.
We recently reported that argon (75%) prevented 
neuronal injury from OGD in vitro but that the protec-
tion aﬀ  orded was inferior to that of xenon [3]. Xenon has 
been shown to be neuroprotective in multiple models 
and species and has now entered clinical trials for 
neonatal hypoxic-ischemic brain injury (TOBYXe; 
NCT00934700) [4,5]. If argon is also to be exploited 
clinically, it too must undergo rigorous exami  nation in 
diﬀ   erent animal models, species, laboratories, and 
clinically relevant injury settings [6]. While at this stage 
argon fulﬁ  lls some criteria, it would be imprudent, in the 
absence of in vivo data, to hail argon as the elusive 
neuroprotective agent.
Why has there been a cascade of studies exploring the 
clinical utility of noble gases [1-5,7,8]? Helium, neon, 
argon, krypton and xenon, the ﬁ  rst ﬁ  ve noble gases in the 
periodic table, contain a full outer shell of electrons, 
precluding the formation of covalent bonds under 
biological conditions; thus, they are chemically inert. Due 
to the uncharged and non-polar nature of their chemical 
composition, these gases are able to easily partition into 
the brain and are able to ﬁ   t snugly into amphiphilic 
binding cavities within proteins [9]. Depending on the 
properties of the surrounding electrons, some of the 
noble gases can create an instantaneous dipole in the 
atom from a charged binding site, thereby promoting a 
biological eﬀ  ect, including induction of anesthesia [10]. 
Neon and helium are thought to create an unfavorable 
balance between binding energies and repulsive forces 
and therefore do not produce anesthesia and other 
biological eﬀ  ects.
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We eagerly await in vivo data to complement the 
promising in vitro data hailing argon neuroprotection.
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© 2010 BioMed Central LtdIn the case of xenon, there are several candidate 
molecules that may be capable of producing the cyto-
protective properties, including the NMDA (N-methyl-
d-aspartic acid) subtype of the glutamate receptor [11], 
the ATP-sensitive potassium channel [12], the two-pore 
potassium channel [13], and an as-yet-unidentiﬁ  ed protein 
that is upstream of mTOR (mammalian target of 
rapamycin) [14]. A reduced ability to form induced 
dipoles with argon (due to its smaller size) may limit the 
number of available protein-binding sites when compared 
with xenon. Indeed, there are important pharmaco-
dynamic diﬀ   erences between xenon and argon; in 
particular, xenon is an anesthetic at atmospheric 
pressure, argon is not [15]. Nonetheless, argon’s lack of 
sedative properties may actually be beneﬁ  cial as it allows 
administration to patients with acute, focal neurological 
injury (such as stroke), who would not necessarily beneﬁ  t 
from sedation. A second major diﬀ  erence involves costs 
and consequent ease of administration. Xenon’s cost 
necessitates administration through cumbersome 
recirculating and recycling systems; argon is substantially 
cheaper and thus may be feasibly administered through 
open circuits.
Th   e development of the noble gases for neuroprotection 
seemed at ﬁ  rst impossible. However, a decade of investi-
gation of the eﬀ  ects of xenon has led to a clinical trial that 
may yet change clinical care of perinatal asphyxia. Th  e 
ﬁ  ndings of Loetscher and colleagues should encourage 
the pursuit of argon as a neuroprotective alternative/
supplement to xenon. Th   at would be a noble venture!
Abbreviation
OGD = oxygen-glucose deprivation.
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